APLLTD

ALEMBIC PHARMACEUTICALS

Mid Cap BSE: 533573 NSE: APLLTD
₹599.8
-2.45 (-0.41%)
  • Advice
  • Hold
As on 30 September, 2022 | 01:26

Alembic Pharmaceuticals Share Price

Alembic Pharmaceuticals Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in ALEMBIC PHARMACEUTICALS

Start SIP

Alembic Pharmaceuticals Share Returns

  • Over 1 Month -7.78%
  • Over 3 Month -18.84%
  • Over 6 Month -21.1%
  • Over 1 Year -24.53%

Alembic Pharmaceuticals Key Statistics

P/E Ratio 37.4
PEG Ratio -0.5
Market Cap Cr 11,790
Price to Book Ratio 2.3
EPS 27.5
Dividend 1.7
Relative Strength Index 26.15
Money Flow Index 42.45
MACD Signal -15.73
Average True Range 13.94

Alembic Pharmaceuticals Investment Rating

  • Master Rating:
  • Alembic Pharmaceuticals has an operating revenue of Rs. 5,241.90 Cr. on a trailing 12-month basis. An annual revenue de-growth of -1% needs improvement, Pre-tax margin of 12% is healthy, ROE of 10% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 31 which is a POOR score indicating inconsistency in earnings, a RS Rating of 8 which is FAIR indicating the recent price performance, Buyer Demand at E which indicates heavy supply, Group Rank of 124 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Alembic Pharmaceuticals Financials
IndicatorJun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021
Oper Rev Qtr Cr 1,1601,3041,2331,1901,2701,157
Operating Expenses Qtr Cr 1,0341,013950953993836
Operating Profit Qtr Cr 127291283237277321
Depreciation Qtr Cr 464645454342
Interest Qtr Cr 964422
Tax Qtr Cr 0041334150
Net Profit Qtr Cr 72251194156193231

Alembic Pharmaceuticals Technicals

EMA & SMA

Current Price
599.8
-2.45 (-0.41%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • 618.29
  • 50 Day
  • 647.95
  • 100 Day
  • 679.34
  • 200 Day
  • 726.01
  • 20 Day
  • 619.3
  • 50 Day
  • 653.14
  • 100 Day
  • 692.21
  • 200 Day
  • 726.23

Alembic Pharmaceuticals Resistance and Support

PIVOT
₹602.84
Resistance
First Resistance 608.67
Second Resistance 615.09
Third Resistance 620.92
RSI 26.15
MFI 42.45
MACD Single Line -15.73
MACD -15.66
Support
First Resistance 596.42
Second Resistance 590.59
Third Resistance 584.17

Alembic Pharmaceuticals Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 178,804 5,653,782 31.62
Week 139,010 4,659,615 33.52
1 Month 144,262 8,600,889 59.62
6 Month 158,423 6,873,960 43.39

Alembic Pharmaceuticals Result Highlights

Alembic Pharmaceuticals Synopsis

NSE-Medical-Generic Drugs

Alembic Pharmaceutic is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 4996.61 Cr. and Equity Capital is Rs. 39.31 Cr. for the Year ended 31/03/2022. Alembic Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 16/06/2010 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ2010PLC061123 and registration number is 061123.
Market Cap 11,637
Sales 4,887
Shares in Float 5.90
No of funds 148
Yield 1.67
Book Value 2.02
U/D Vol ratio 0.4
LTDebt / Equity 4
Alpha -0.1
Beta 0.56

Alembic Pharmaceuticals

Owner NameJun-22Mar-22Dec-21Sep-21
Promoters 69.61%69.61%69.48%
Mutual Funds 5.01%5.18%4.95%
Insurance Companies 7.01%6.48%6.57%
Foreign Portfolio Investors 5.94%6.02%5.89%
Financial Institutions/ Banks 0.04%0.04%0.04%
Individual Investors 8.91%9.22%9.57%
Others 3.48%3.45%3.5%

Alembic Pharmaceuticals Management

Name Designation
Mr. Chirayu Amin Chairman & CEO
Mr. Pranav Amin Managing Director
Mr. Shaunak Amin Managing Director
Mr. R K Baheti Director - Finance & CFO
Mr. K G Ramanathan Independent Director
Mr. Pranav Parikh Independent Director
Mr. Paresh Saraiya Independent Director
Dr. Archana Hingorani Independent Director

Alembic Pharmaceuticals Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Alembic Pharmaceuticals Corporate Action

Date Purpose Remarks
2022-08-04 Quarterly Results & Others To change dividend type from Final Dividend to Interim Dividend consider and approve the issue and allotment of Unsecured Redeemable Non-Convertible Debentures (NCDs) of upto Rs. 350 Crores on Private Placement Basis.
2022-05-02 Audited Results & Dividend
2022-02-10 Quarterly Results
2021-11-10 Quarterly Results
2021-07-26 Quarterly Results
Date Purpose Remarks
2022-08-18 INTERIM Rs.10.00 per share(500%)Dividend (Changed Final Dividend as Interim Divided)

Alembic Pharmaceuticals MF Shareholding

Name Amount(cr)
HDFC Mid-Cap Opportunities Fund Growth 34227
Kotak Equity Arbitrage Fund Growth 23310
DSP Midcap Fund Growth 14378
ICICI Prudential Equity Arbitrage Fund Regular Growth 11507
DSP Tax Saver Fund Regular Plan Growth 10219

Alembic Pharmaceuticals FAQs

What is Share Price of Alembic Pharmaceuticals ?

Alembic Pharmaceuticals share price is ₹599 As on 30 September, 2022 | 01:12

What is the Market Cap of Alembic Pharmaceuticals ?

The Market Cap of Alembic Pharmaceuticals is ₹11789.9 Cr As on 30 September, 2022 | 01:12

What is the P/E ratio of Alembic Pharmaceuticals ?

The P/E ratio of Alembic Pharmaceuticals is 37.4 As on 30 September, 2022 | 01:12

What is the PB ratio of Alembic Pharmaceuticals ?

The PB ratio of Alembic Pharmaceuticals is 2.3 As on 30 September, 2022 | 01:12

Q1FY23